Literature DB >> 12454730

Sensitization of cortical acetylcholine release by repeated administration of nicotine in rats.

H Moore Arnold1, Christopher L Nelson, Martin Sarter, John P Bruno.   

Abstract

RATIONALE: The integrity of cortical cholinergic transmission is vital to attentional processing. A growing literature suggests that alterations in attentional processing accompany addictive drug use. This study examined the effects of acute and repeated administration of nicotine on cortical acetylcholine release.
OBJECTIVES: The effects of repeated systemic nicotine administration on cortical acetylcholine (ACh) efflux in the frontal cortex were determined to test the hypothesis that repeated administration of nicotine results in a potentiated or sensitized increase in ACh efflux.
METHODS: Animals were injected with nicotine (0.4 mg/kg, i.p.) or vehicle twice daily for 4 days. Cortical ACh efflux was measured using repeated microdialysis sampling on four occasions: on day 1, during the first exposure to nicotine or vehicle, on day 5 during a final exposure to nicotine, on day 8 during a nicotine challenge, and again on day 10 following saline administration.
RESULTS: Acute nicotine administration on day 1 produced a 90% increase in cortical ACh efflux. Repeated exposure to nicotine resulted in a larger increase in cortical ACh efflux on day 5 (200%) and day 8 (210%) relative to ACh levels measured on day 1, and relative to animals that received vehicle during the initial treatment period. Cortical ACh efflux following acute nicotine administration was blocked by mecamylamine (1.0 mg/kg, i.p.). However, the sensitized efflux of cortical ACh on day 8 was only partially attenuated by mecamylamine (1.0 or 5.0 mg/kg, i.p.), suggesting a mecamylamine-insensitive component of the sensitized response to repeated nicotine administration.
CONCLUSIONS: Repeated administration of nicotine results in a sensitized increase in cortical ACh release. Sensitized cortical ACh release may mediate, in part, the cognitive components of nicotine addiction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454730     DOI: 10.1007/s00213-002-1260-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility study.

Authors:  Rebecca L Ashare; Riju Ray; Caryn Lerman; Andrew A Strasser
Journal:  Drug Alcohol Depend       Date:  2012-05-15       Impact factor: 4.492

Review 2.  Regulation of cortical acetylcholine release: insights from in vivo microdialysis studies.

Authors:  Jim R Fadel
Journal:  Behav Brain Res       Date:  2010-02-16       Impact factor: 3.332

3.  3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.

Authors:  Sunila G Nair; Gary A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

Review 4.  Orexin/hypocretin modulation of the basal forebrain cholinergic system: Role in attention.

Authors:  J Fadel; J A Burk
Journal:  Brain Res       Date:  2009-08-21       Impact factor: 3.252

Review 5.  Microdialysis and the neurochemistry of addiction.

Authors:  Mary M Torregrossa; Peter W Kalivas
Journal:  Pharmacol Biochem Behav       Date:  2007-09-12       Impact factor: 3.533

6.  Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats.

Authors:  Blake A Kimmey; Laura E Rupprecht; Matthew R Hayes; Heath D Schmidt
Journal:  Addict Biol       Date:  2012-12-12       Impact factor: 4.280

7.  The antisaccade task as an index of sustained goal activation in working memory: modulation by nicotine.

Authors:  Nicola Rycroft; Samuel B Hutton; Jennifer M Rusted
Journal:  Psychopharmacology (Berl)       Date:  2006-08-01       Impact factor: 4.530

8.  Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence.

Authors:  Riju Ray; Nandita Mitra; Don Baldwin; Mengye Guo; Freda Patterson; Daniel F Heitjan; Christopher Jepson; E Paul Wileyto; Jinxue Wei; Thomas Payne; Jennie Z Ma; Ming D Li; Caryn Lerman
Journal:  Neuropsychopharmacology       Date:  2010-02-10       Impact factor: 7.853

9.  The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.

Authors:  Mei Huang; Anna R Felix; Dorothy G Flood; Chaya Bhuvaneswaran; Dana Hilt; Gerhard Koenig; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

10.  Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.

Authors:  Jonathan D Raybuck; George S Portugal; Caryn Lerman; Thomas J Gould
Journal:  Behav Neurosci       Date:  2008-10       Impact factor: 1.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.